EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
about
Mobile phone text messaging to improve adherence to cardiovascular disease secondary prevention interventionsRole of colesevelam in combination lipid-lowering therapyTreatment of dyslipidemiaUnder-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective AnalysisMobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease.Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment.Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry.The effectiveness of the cardiovascular disease prevention programme 'KardioPro' initiated by a German sickness fund: a time-to-event analysis of routine data.Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represRegional differences in self-reported screening, prevalence and management of cardiovascular risk factors in Switzerland.The effects of Hartcoach, a life style intervention provided by telephone on the reduction of coronary risk factors: a randomised trial.Randomized controlled trial on cardiovascular risk management by practice nurses supported by self-monitoring in primary care.Cardiovascular screening in general practice in a low SES area.Economic efficiency of primary care for CVD prevention and treatment in Eastern European countriesImplementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary care.Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysisComparing the effectiveness of two cardiovascular prevention programmes for highly educated professionals in general practice: a randomised clinical trialWhich patient and treatment factors are related to successful cardiovascular risk score reduction in general practice? Results from a randomized controlled trialAntihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium erinaceus in experimental diabetic rats.Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population.Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyNebivolol: impact on cardiac and endothelial function and clinical utility.The perception and knowledge of cardiovascular risk factors among medical students.Prevalence and Incidence of Hypertension in the General Adult Population: Results of the CARLA-Cohort Study.Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach.The effect of problem-based learning in patient education after an event of CORONARY heart disease--a randomised study in PRIMARY health care: design and methodology of the COR-PRIM studyPrevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular PharmacoloEffectiveness of a quality improvement intervention targeting cardiovascular risk factors: are patients responsive to information and encouragement by mail or post?Awareness, treatment, and control of major cardiovascular risk factors in a small-scale Italian community: results of a screening campaign.Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trialMissed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional studyStatins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts.Determinants of preferences for lifestyle changes versus medication and beliefs in ability to maintain lifestyle changes. A population-based survey.Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care.Emerging options in the treatment of dyslipidemias: a bright future?Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia.Emerging drugs for hyperlipidaemia: an update.
P2860
Q24188063-BD98F03E-BF12-4849-9347-3732198059B6Q27016027-670293C6-3271-4C29-9E23-4F6E2829A103Q27026114-16529481-81B8-4235-B8C2-80B7085CB46DQ28553496-9C99CBEC-5370-49E1-B718-618B60D48959Q30234608-ADABC109-5057-477F-9A20-634D18FA84D9Q30489448-BE1925E2-145C-4CE7-BE7D-70F3335B5FEBQ30844230-D16E1FD8-C2FE-48FE-8758-F2A54B4697C9Q30875843-95407318-2F69-4F25-A83C-7A5F571CF23AQ34020986-61C80075-4747-4F1F-82B8-15267671DC32Q34046881-5EB6E5AC-388F-442B-88D8-7293079338F6Q34209455-35C12A85-1352-429D-83CA-7619D63BA1F5Q34317443-03409EE2-5560-41C9-82A0-9950302D9D34Q34402860-C54E2604-907A-4154-AC38-0A3909ACA3C2Q34507659-D4F52C61-3D66-4EE4-9387-004E0EDBB508Q34596862-A3AA2D01-9D5F-4091-B153-BBC126637E65Q34626513-FB52C2F0-BA9C-40F5-A0B5-DFED8B949EC0Q34677382-B47CC55D-B893-438B-9315-CC3C153DAF67Q34750530-9DFC8761-359F-4D48-9977-30AFE27B618EQ34966833-DF603BC4-F122-4EAE-BE23-47D1CADEB16BQ35007400-757C23D3-9853-494E-97F3-AB45F85FF87AQ35178417-F0E84CE9-A919-4E99-B2F1-84A6FDE42879Q35187425-F9BC9A59-B06C-48DA-994D-91100AAF657CQ35846698-7A13885A-DF5A-47A0-BFF8-81802E256499Q36045185-B6CC9DFA-7C5C-4EF0-8C0F-6B1F1B685E7AQ36193654-B6BE668E-3F3C-4F72-B66D-ACC058332FD1Q36370431-4BFD0B15-6FD7-40B3-92B0-97DA1882A872Q36483413-AA3DD2A4-2554-484B-8124-61F62CE3CD3DQ36613362-139A590D-C452-4A68-B292-B249A31EFB5CQ36620506-C17E0A77-18D8-4D2F-BE69-DF329D95897BQ36822614-87968956-F190-4232-9C03-54D727D503B6Q37106358-2BE2B964-C90A-4994-B224-157A5121599CQ37421111-DFF3B2CB-583D-4477-9862-851494C4A0F4Q37424595-1736273B-409E-4BBC-A384-CB3FC12A41E0Q37672601-5989D392-A39E-4A93-B060-12A9F7642F48Q37682234-E6E32AFD-8D82-4BE4-8A94-300B4C2A0ACFQ37842462-57EFF3BB-6D1C-40B1-A865-5D6EB2375A1FQ38049151-614D6982-84CC-452D-9B9D-045E1FFC9FFFQ38065321-D538A307-0C40-4038-A93E-97E533DF3CE1Q38219487-2A0884AC-5EA7-4F05-B4F2-34A7FA359B3AQ38263909-2EB45BB6-A068-4B8F-81B4-D258C9470932
P2860
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
EUROASPIRE III. Management of ...... rvey in 12 European countries.
@en
EUROASPIRE III. Management of ...... rvey in 12 European countries.
@nl
type
label
EUROASPIRE III. Management of ...... rvey in 12 European countries.
@en
EUROASPIRE III. Management of ...... rvey in 12 European countries.
@nl
prefLabel
EUROASPIRE III. Management of ...... rvey in 12 European countries.
@en
EUROASPIRE III. Management of ...... rvey in 12 European countries.
@nl
P2093
P2860
P1476
EUROASPIRE III. Management of ...... rvey in 12 European countries.
@en
P2093
David Wood
Dirk De Bacquer
EUROASPIRE Study Group
Kalevi Pyörälä
Kornelia Kotseva
Ulrich Keil
Zeljko Reiner
P2860
P304
P356
10.1097/HJR.0B013E3283383F30
P577
2010-10-01T00:00:00Z